Open Access Repository
New insights and long-term safety of tocilizumab in rheumatoid arthritis

Full text not available from this repository.
Abstract
Rheumatoid arthritis is a leading musculoskeletal cause of disability in Western society. Therapeutic options have expanded rapidly with the advent of biological agents as treatment options. One of these, tocilizumab, targets the interleukin-6 receptor and has been approved since the late 2000s in many jurisdictions. This approval was based on 6-12 month trials. It is now appropriate to look at longer-term studies and what new insights they have provided into this agent. Data are based largely on observational studies with their well-known limitations as well as some further randomized trials and provide a number of important observations regarding both efficacy and safety. In conclusion, the longer-term data suggest tocilizumab efficacy increases over time for both signs and symptoms and radiographic change. It is also corticosteroid sparing. The safety data are consistent with the shorter-term trials and are largely reassuring but some questions still remain over cardiovascular safety and cancer risk.
Item Type: | Article |
---|---|
Authors/Creators: | Jones, G and Panova, E |
Keywords: | cohort, database, long term, rheumatoid, tocilizumab, trials |
Journal or Publication Title: | Therapeutic Advances in Musculoskeletal Disease |
Publisher: | Sage Publications Ltd. |
ISSN: | 1759-720X |
DOI / ID Number: | 10.1177/1759720X18798462 |
Copyright Information: | Copyright 2018 The Authors |
Related URLs: | |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |